GlycoMimetics Inc (GLYC)
0.3994
0.00 (0.00%)
USD |
NASDAQ |
Nov 14, 16:00
0.3989
0.00 (0.00%)
After-Hours: 07:45
GlycoMimetics Net Income (TTM): -39.11M for June 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | -39.11M |
| March 31, 2024 | -37.28M |
| December 31, 2023 | -36.90M |
| September 30, 2023 | -38.07M |
| June 30, 2023 | -37.39M |
| March 31, 2023 | -42.40M |
| December 31, 2022 | -46.69M |
| September 30, 2022 | -53.87M |
| June 30, 2022 | -62.67M |
| March 31, 2022 | -63.81M |
| December 31, 2021 | -63.43M |
| September 30, 2021 | -61.57M |
| June 30, 2021 | -57.96M |
| March 31, 2021 | -57.64M |
| December 31, 2020 | -51.03M |
| September 30, 2020 | -50.19M |
| June 30, 2020 | -49.72M |
| March 31, 2020 | -51.47M |
| December 31, 2019 | -57.89M |
| September 30, 2019 | -57.07M |
| June 30, 2019 | -55.40M |
| March 31, 2019 | -50.84M |
| December 31, 2018 | -48.27M |
| Date | Value |
|---|---|
| September 30, 2018 | -43.62M |
| June 30, 2018 | -40.00M |
| March 31, 2018 | -36.86M |
| December 31, 2017 | -33.28M |
| September 30, 2017 | -32.35M |
| June 30, 2017 | -32.26M |
| March 31, 2017 | -32.19M |
| December 31, 2016 | -31.81M |
| September 30, 2016 | -32.36M |
| June 30, 2016 | -31.68M |
| March 31, 2016 | -13.22M |
| December 31, 2015 | -12.77M |
| September 30, 2015 | -11.28M |
| June 30, 2015 | -10.73M |
| March 31, 2015 | -13.13M |
| December 31, 2014 | -11.12M |
| September 30, 2014 | -7.595M |
| June 30, 2014 | -4.678M |
| March 31, 2014 | -16.17M |
| December 31, 2013 | -10.61M |
| September 30, 2013 | -6.100M |
| June 30, 2013 | -1.577M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-63.81M
Minimum
Mar 2022
-36.90M
Maximum
Dec 2023
-50.48M
Average
-51.03M
Median
Dec 2020
Net Income (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 322.29M |
| Arbutus Biopharma Corp | -76.70M |
| Revance Therapeutics Inc | -184.44M |
| FibroGen Inc | -168.32M |
| Cidara Therapeutics Inc | -120.73M |